Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands

Diabetic Medicine

Volumn 29, Issue 3, 2012, Pages 303-312

  Valentine, W J ^a   Jendle, J ^b   Saraheimo, M ^c   Thorsteinsson, B ^d,e   Pollock, R F ^a   Lammert, M ^f  

^a Ossian Health Economics and Communications GmbH   (Switzerland)

^b Örebro University   (Sweden)

^c UNIVERSITY OF HELSINKI   (Finland)

^d HILLERØD HOSPITAL   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f NOVO NORDISK A S   (Denmark)

Author keywords

Analogues; Economics; Hypoglycaemia; Type1 diabetes

Indexed keywords

INSULIN DETEMIR; ISOPHANE INSULIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DENMARK; DRUG COST; DRUG EFFICACY; FINLAND; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NETHERLANDS; QUALITY ADJUSTED LIFE YEAR; SWEDEN;

COST-BENEFIT ANALYSIS; DENMARK; DIABETES MELLITUS, TYPE 1; FEMALE; FINLAND; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; NETHERLANDS; PHARMACIES; QUALITY-ADJUSTED LIFE YEARS; SWEDEN;

EID: 84857352907     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03461.x     Document Type: Article

References (32)

1. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Hypoglycaemia Study Group. Risk of hypoglycaemia in types1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140-1147.
3. Gschwend MH, Aagren M, Valentine WJ. Cost-effectiveness of insulin detemir compared with neutral protamine Hagedorn insulin in patients with type1 diabetes using a basal-bolus regimen in five European countries. J Med Econ 2009; 12: 114-123.
4. Tunis SL, Minshall ME, Conner C, McCormick JI, Kapor J, Yale JF et al. Cost-effectiveness of insulin detemir compared to NPH insulin for type1 and type2 diabetes mellitus in the Canadian payer setting: modeling analysis. Curr Med Res Opin 2009; 25: 1273-1284.
5. Palmer AJ, Lammert M, Hermansen K. Sundhedsøkonomiske konsekvenser af insulinanaloger til behandling af type 1-diabetes i Danmark (Health economic consequences of insulin analogues in the treatment of type1 diabetes in Denmark). Ugeskr Laeger 2008; 170: 1250-1254.
6. Palmer AJ, Valentine WJ, Ray JA, Foos V, Lurati F, Smith I et al. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type1 diabetes in the UK. Curr Med Res Opin 2007; 23: 895-901.
7. Palmer AJ, Roze S, Valentine WJ, Smith I, Wittrup-Jensen KU. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. Curr Med Res Opin 2004; 20: 1729-1746.
8. Levy AR, Christensen TL, Johnson JA. Utility values for symptomatic non-severe hypoglycaemia elicited from persons with and without diabetes in Canada and the UK. Health Qual Life Outcomes 2008; 6: 73.
9. Marrett E, Stargardt T, Mavros P, Alexander CM. Patient-reported outcomes in a survey of patients treated with oral anti-hyperglycaemic medications: associations with hypoglycaemia and weight gain. Diabetes Obes Metab 2009; 11: 1138-1144.
10. NICE. Guidance on the Use of Long-Acting Insulin Analogues for the Treatment of Diabetes - Insulin Glargine. Technology appraisal guidance no.53. 2002. Available at Last accessed 21 October 2009.
11. Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22: 1523-1534.
12. Davis RE, Morrissey M, Peters JR, Wittrup-Jensen K, Kennedy-Martin T, Currie CJ. Impact of hypoglycaemia on quality of life and productivity in type1 and type2 diabetes. Curr Med Res Opin 2005; 21: 1477-1483.
13. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ 2005; 6: 197-202.
14. Nordfeldt S, Ludvigsson J. Fear and other disturbances of severe hypoglycemia in children and adolescents with type1 diabetes mellitus. J Pediatr Endocrinol Metab 2005; 18: 83-91.
15. Matza LS, Boye KS, Yurgin N, Brewster-Jordan J, Mannix S, Shorr JM et al. Utilities and disutilities for type2 diabetes treatment-related attributes. Qual Life Res 2007; 16: 1251-1265.
16. Canadian Agency for Drugs and Technology in Health. Long-Acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes - Update of CADTH Technology Report No.92. COMPUS Vol.2, Issue1, March 2008. Available at Last accessed 21 October 2009.
17. WHO. CHOosing Interventions that are Cost Effective (CHOICE) Program. Available at Last accessed 22 October 2009.
18. International Monetary Fund. World Economic Outlook Database-April 2010. Available at Last accessed 7 July 2010.
19. Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to neutral protamine Hagedorn insulin in patients with Type1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008; 25: 442-449.
20. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type1 diabetes. A meta-analysis. Diabetes Obes Metab 2009; 11: 372-378.
21. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001; 24: 296-301.
22. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-596.
23. Kølendorf K, Ross GP, Pavlic-Renar I, Perriello G, Philotheou A, Jendle J et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type1 diabetes. Diabet Med 2006; 23: 729-735.
24. Home P, Bartley P, Russell-Jones D, Hanaire-Broutin H, Heeg JE, Abrams P et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27: 1081-1087.
25. Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007; 24: 27-34.
26. De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E et al. Insulin detemir used in basal-bolus therapy in people with type1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
27. Pramming S, Thorsteinsson B, Bendtson I, Binder C. Symptomatic hypoglycaemia in 411 Type1 diabetic patients. Diabet Med 1991; 8: 217-222.
28. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type1 diabetes mellitus. Lancet 2001; 357: 1248-1253.
29. Janssen MM, Snoek FJ, de Jongh RT, Casteleijn S, Devillé W, Heine RJ. Biological and behavioural determinants of the frequency of mild, biochemical hypoglycaemia in patients with Type1 diabetes on multiple insulin injection therapy. Diabetes Metab Res Rev 2000; 16: 157-163.
30. Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S, Hougaard P, Thorsteinsson B. Prediction of severe hypoglycaemia by angiotensin-converting enzyme activity and genotype in type1 diabetes. Diabetologia 2003; 46: 89-96.
31. Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jørgensen HV et al. Severe hypoglycaemia in 1076 adult patients with type1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev 2004; 20: 479-486.
32. Donnelly LA, Morris AD, Frier BM, Ellis JD, Donnan PT, Durrant R et al. DARTS/MEMO Collaboration. Frequency and predictors of hypoglycaemia in Type1 and insulin-treated Type2 diabetes: a population-based study. Diabet Med 2005; 22: 749-755.